Credits: Canva
After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.
With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.
The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.
So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).
Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.
The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.
As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.
This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.
As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.
The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.
The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.
In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.
However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.
Credit: AI-generated image
The United States has lost its measles elimination status after more than a year of sustained transmission, marking a major setback for a public health achievement the country obtained in 2000.
The decision by the Pan American Health Organization (PAHO) comes after a sharp rise in infections as the US reported more than 5,400 measles cases in 2026. PAHO is expected to formally announce the decision on November 17.
According to the US Centers for Disease Control and Prevention (CDC), the country had recorded 5,412 cases as of November 15, resulting in more than 590 hospitalisations and at least six deaths. Some states have reported additional fatalities. Cases have been confirmed in 45 states and Washington, DC.
The United States had maintained its measles elimination status for more than 25 years. However, outbreaks that began in 2025 continued spreading into 2026. Approximately one-third of this year's cases were linked to those ongoing outbreaks.
Measles elimination does not mean a country has no cases of the disease. It means that local transmission has been interrupted and that occasional outbreaks do not lead to sustained community spread.
Under the World Health Organization's definition, a country loses elimination status when it cannot stop continuous local transmission for at least 12 months.
The United States first achieved measles elimination status in 2000, after decades of vaccination efforts dramatically reduced infections. Imported cases and smaller outbreaks still occurred, but public-health measures and vaccination coverage helped contain them.
The current situation is different because the virus has continued circulating through communities for more than a year, creating ongoing chains of transmission.
CBS News medical correspondent Dr Céline Gounder explained the implications, "It means that we're at risk of being exposed to measles and getting measles if we're not vaccinated," Gounder said. "It means ERs and pediatricians need to consider measles in anyone with a fever and rash, whether they've traveled overseas or not. And we may now become an exporter of measles to other countries."
Also read: US Measles Cases Cross 5,000 For First Time Since 1991; Country Risks Losing Elimination Status
Declining childhood vaccination coverage has left more communities vulnerable to outbreaks. Measles is among the most contagious infectious diseases, and the virus can spread rapidly when it enters populations with gaps in immunity.
According to CDC data, 96% of people infected in 2026 were either unvaccinated or had an unknown vaccination status. Only 2% of reported cases were among people who were fully vaccinated.
The country recorded 2,242 cases in 2025, its highest annual total in more than three decades at the time. The number has more than doubled in 2026.
Pennsylvania has reported the largest outbreak, with more than 1,500 cases and seven deaths this year. Wisconsin has reported two child deaths, while New York recorded its first measles death in more than 30 years.
People who have not received the measles vaccine are at the greatest risk of infection. However, infants who are too young to be vaccinated, pregnant women and people with weakened immune systems are the most vulnerable.
Measles can cause complications like pneumonia and encephalitis or inflammation of the brain. In some cases, it can lead to permanent neurological complications, hearing loss and death.
Children who have not received the recommended doses of the measles, mumps and rubella (MMR) vaccine are especially vulnerable.
The CDC recommends two doses of the MMR vaccine. According to the public health experts, two doses are approximately 97% effective against measles.
Losing elimination status does not mean the country cannot regain it. However, sustained efforts to interrupt transmission will be necessary.
PAHO recommends maintaining measles vaccination coverage of at least 95%, alongside strong disease surveillance, laboratory testing and rapid outbreak response. Dr Omer Awan, an epidemiologist and public health contributor for Forbes, explained the importance of vaccination.
"It's frustrating and heartbreaking ... because we have the tools to fight this. The tool is the MMR vaccine, which we know is 97% effective at preventing the onset of measles," Awan said.
Credit: AI-generated image
Eli Lilly is rapidly expanding its presence in the global obesity treatment market. Its oral weight-loss drug Foundayo has received approval in China, becoming the first GLP-1 pill to get approved in the country.
In another development, its experimental drug combination of eloralintide and tirzepatide recently reported substantial weight loss in an early-stage clinical trial.
The developments come as pharmaceutical companies compete to develop more convenient treatments for obesity, including oral alternatives to injections and dual and triple-acting medicines.
RecnChina approved orforglipron, marketed as Foundayo in the US, making it the first GLP-1 medication in pill form approved for weight management in the country. Until now, Chinese regulators had authorised GLP-1 medicines for obesity treatment only as injections.
The approval gives Lilly an early advantage over its rival Novo Nordisk, which has also applied to market its oral Wegovy treatment in China.
Foundayo contains orforglipron, an oral, small-molecule GLP-1 receptor agonist. GLP-1 medicines mimic the action of a naturally occurring gut hormone involved in appetite regulation and blood sugar control.
Unlike injectables like Wegovy and Zepbound, Foundayo is taken once daily as a tablet. It can also be taken without restrictions on food and water intake, which may make it a more convenient option for people who prefer not to use injections.
In separate clinical trials, Foundayo produced an average weight reduction of approximately 11% over 72 weeks, while oral Wegovy achieved around 14% over 64 weeks. These results come from different studies.
Also read: Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric Symptoms
In another development announced on November 14, Lilly reported promising Phase 2 results for EloraTZP, an experimental combination of eloralintide and tirzepatide.
The combination brings together two medicines that act on appetite and metabolism differently. Tirzepatide, the active ingredient in Zepbound, activates GIP and GLP-1 receptors. Eloralintide is an investigational drug that acts on amylin receptors, which are involved in regulating appetite and feelings of fullness.
In adults with obesity and type 2 diabetes, participants receiving EloraTZP achieved weight loss of up to an average of 23.3% after 48 weeks. Their average starting weight was 232.4 pounds (approximately 105.4 kg). Up to 60% of participants no longer met the BMI criteria for obesity at the end of the study.
The combination also reduced the average blood glucose levels over approximately three months, by up to 2.9 percentage points. Up to 77% of participants achieved normal blood sugar levels, according to Lilly.
However, these are Phase 2 findings reported by Lilly, and the full trial results have not yet been published. Larger studies will be needed to establish the combination's safety and effectiveness in obesity treatment.
Lilly's latest update included findings from its Phase 3 SURMOUNT-ADOLESCENTS trials, which evaluated Zepbound in adolescents aged 12 to under 18 with obesity.
Participants experienced an average BMI reduction of 21.4% after 72 weeks. More than half no longer met the BMI criteria for obesity. They also reported improvements in aspects of quality of life due to weight reduction, including physical comfort and better body image.
Separately, the company reported Phase 3 findings for retatrutide, an experimental once-weekly medicine that activates three hormone receptors: GIP, GLP-1 and glucagon.
In trials involving adults with obesity, it reduced the severity of obstructive sleep apnoea and knee osteoarthritis pain. Retatrutide, an investigational drug, is not approved for general medical use.
Credit: AI-generated image
Air pollution in India, especially during winter after Diwali, is one of the alarming environmental and health concerns currently. While we are aware about its adverse effects on lungs and respiratory health, a recent review of five decades of Indian research has suggested its damages may extend to other bodily functions too.
A review of five decades of Indian research has found that more than 91% of epidemiological studies examining the health effects of air pollution reported at least one adverse health effect. These health conditions ranged from cardiovascular and metabolic diseases to pregnancy complications and cancer.
The analysis, conducted by the Centre for Research on Energy and Clean Air (CREA), examined 184 peer reviewed epidemiological studies published between 1975 and 2025.
Out of these, 169 reported at least one positive link between air pollution and an adverse health effect. The findings cement evidence linking polluted air to a wider range of health problems.
Also read: World Diabetes Day 2026: Is India's Toxic Air Adding To Its Diabetes Crisis? What Experts Say
Respiratory diseases were the most frequently investigated health outcomes, featuring in 86 of the 184 studies. Sixteen studies examined mortality, while 11 focused on cardiovascular diseases.
Other research investigated connections between air pollution and diabetes, pregnancy complications, low birth weight, impaired child growth, cancers and other neoplasms, blood disorders, neurological and mental health conditions, metabolic disorders, sleep problems, eye diseases and chronic kidney and bone conditions.
The review also found that the evidence was not limited to privately funded or independent research. Of the 46 government-funded studies included, 44 reported increased health risks.
Similarly, 77 of the 81 studies affiliated with government institutions reported adverse health associations. These institutions included the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), the Central Pollution Control Board (CPCB) and the Ministry of Health and Family Welfare.
The 91.8% figure represents the proportion of studies that reported at least one positive association with a health outcome.
Delhi accounted for the highest number of studies i.e. 26, followed by Punjab with 13, and Maharashtra and Uttar Pradesh with 11 each. However, the review also highlighted a wide gap in research outside urban centres.
Only 40 studies examined rural populations. Of these, 38 reported at least one adverse health effect linked with air pollution exposure.
The studies accounted for several sources of exposure, including outdoor pollution, household cooking and heating fuels, indoor environments like homes and workplaces, and occupational exposure.
Also read: Delhi Air Pollution: Are Online Classes And Indoor Time Adding To Children's Anxiety?
Fine particulate matter, like PM2.5, can travel deep into the lungs and enter the bloodstream. It can cause inflammation and oxidative stress, processes that may affect blood vessels, metabolic regulation and other organs.
Indian research has also examined the relationship between PM2.5 exposure and type 2 diabetes. A study involving 12,064 adults in Delhi and Chennai, published in BMJ Open Diabetes Research & Care in 2023, found that higher long-term PM2.5 exposure was associated with increased fasting blood glucose, HbA1c and the risk of developing type 2 diabetes. The findings were observational and do not establish that pollution alone caused diabetes.
Air pollution has also been associated with cardiovascular conditions, including hypertension, ischaemic heart disease and stroke. Meanwhile, the CREA review included studies examining neoplasms, a category that includes cancers. However, the review does not establish that 91% of studies independently linked pollution to diabetes, heart disease and cancer. These were among several health outcomes investigated.
The review suggests that air pollution policies need to address the wider picture. Studies examined particulate matter, including PM2.5 and PM10, as well as nitrogen dioxide, sulphur dioxide, ozone, carbon monoxide, black carbon and heavy metals.
CREA has called for stronger air-quality standards, better pollution monitoring, stricter emission limits for industries and power plants, and measures to reduce indoor pollution from solid fuels. It has also emphasised the need to include rural populations in the next phase of India's National Clean Air Programme.
© $2026 Times Horizon Private Limited